Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Bradley A. McGregor, MD, director of Clinical Research for the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, discusses the advancements in treating metastatic renal cell ...

Jacob Sands, MD, discusses the benefits of the arrival of Dato-DXd into the EGFR-positive non–small cell lung cancer treatment landscape and the next steps in research for this agent.

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.